Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Tsurutani

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
Chinese Clinical Oncology|April 6, 2015
Perspectives in drug development for cancer therapy in AsiaKazuhiko Nakagawa, Junji Tsurutani
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Resistant mechanisms against breast cancer treatment and therapeutic strategies]Junko Tanizaki, Junji Tsurutani
Journal of the National Cancer Institute|December 2, 2004
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancerJunji Tsurutani, Phillip A Dennis
Breast Cancer (Tokyo, Japan)|January 29, 2025
Management of nausea and vomiting induced by antibody-drug conjugatesJawhara Farhat, Hitomi Sakai, Junji Tsurutani
Breast Cancer (Tokyo, Japan)|October 17, 2018
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational studyJunji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka
Breast Cancer (Tokyo, Japan)|January 31, 2026
Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecanJunji Tsurutani, Kengo Noguchi, Ayumi Tanabe
Biomolecules|October 29, 2025
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung CancerRichy Ekyalongo, Toshimitsu Yamaoka, Junji Tsurutani
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinomaJunji Tsurutani, Marc S Ballas, Phillip A Dennis
Translational Lung Cancer Research|November 19, 2020
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancerToshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, et al.
Journal of Visualized Experiments : Jove|July 16, 2019
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of AfatinibToshimitsu Yamaoka, Motoi Ohba, Yuki Matsunaga, et al.
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
Chinese Clinical Oncology|April 6, 2015
Perspectives in drug development for cancer therapy in AsiaKazuhiko Nakagawa, Junji Tsurutani
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Resistant mechanisms against breast cancer treatment and therapeutic strategies]Junko Tanizaki, Junji Tsurutani
Journal of the National Cancer Institute|December 2, 2004
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancerJunji Tsurutani, Phillip A Dennis
Breast Cancer (Tokyo, Japan)|January 29, 2025
Management of nausea and vomiting induced by antibody-drug conjugatesJawhara Farhat, Hitomi Sakai, Junji Tsurutani
Breast Cancer (Tokyo, Japan)|October 17, 2018
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational studyJunji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka
Breast Cancer (Tokyo, Japan)|January 31, 2026
Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecanJunji Tsurutani, Kengo Noguchi, Ayumi Tanabe
Biomolecules|October 29, 2025
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung CancerRichy Ekyalongo, Toshimitsu Yamaoka, Junji Tsurutani
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinomaJunji Tsurutani, Marc S Ballas, Phillip A Dennis
Translational Lung Cancer Research|November 19, 2020
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancerToshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, et al.
Journal of Visualized Experiments : Jove|July 16, 2019
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of AfatinibToshimitsu Yamaoka, Motoi Ohba, Yuki Matsunaga, et al.
Pageof 17